Serum 25-hydroxyvitamin D level and influenza vaccine immunogenicity in children and adolescents

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Science, Michelle ^a,b   Maguire, Jonathon L ^c,d,e,f   Russell, Margaret L ^g   Smieja, Marek ^b   Walter, Stephen D ^b   Loeb, Mark ^b,h  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; INFLUENZA VACCINE;

ADOLESCENT; AGE DISTRIBUTION; ANTIBODY TITER; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHOOL CHILD; SENSITIVITY ANALYSIS; SEROCONVERSION; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; VACCINATION; VITAMIN D;

EID: 84897507746     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083553     Document Type: Article

References (29)

1. Nicholson KG, Wood JM, Zambon M (2003) Influenza. Lancet 362: 1733-1745. (Pubitemid 37468326)
2. Barr IG, McCauley J, Cox N, Daniels R, Engelhardt OG, et al. (2010) Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 Northern Hemisphere season. Vaccine 28: 1156-1167.
3. Ahmed AH, Nicholson KG (1996) The Efficacy of Influenza Vaccine. Reviews in Medical Microbiology 7: 23-30. (Pubitemid 26044793)
4. Jackson LA, Chen WH, Stapleton JT, Dekker CL, Wald A, et al. (2012) Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis 206: 811-820.
5. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ (2009) Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 200: 172-180.
6. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, et al. (2008) Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 198: 650-658.
7. Oberg F, Botling J, Nilsson K (1993) Functional antagonism between vitamin D3 and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells. J Immunol 150: 3487-3495. (Pubitemid 23129729)
8. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, et al. (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773.
9. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, et al. (2004) Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 173: 2909-2912. (Pubitemid 39141992)
10. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, et al. (2001) 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 167: 4974-4980. (Pubitemid 33009728)
11. van Etten E, Mathieu C (2005) Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 97: 93-101.
12. Chen S, Sims GP, Chen XX, Gu YY, Lipsky PE (2007) Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179: 1634-1647.
13. Daynes RA, Enioutina EY, Butler S, Mu HH, McGee ZA, et al. (1996) Induction of common mucosal immunity by hormonally immunomodulated peripheral immunization. Infect Immun 64: 1100-1109. (Pubitemid 26102368)
14. Daynes RA, Araneo BA (1994) The development of effective vaccine adjuvants employing natural regulators of T-cell lymphokine production in vivo. Ann N Y Acad Sci 730: 144-161. (Pubitemid 24292208)
15. Kriesel JD, Spruance J (1999) Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. Vaccine 17: 1883-1888. (Pubitemid 29172356)
16. Cooper C, Thorne A (2011) Vitamin D supplementation does not increase immunogenicity of seasonal influenza vaccine in HIV-infected adults. HIV Clin Trials 12: 275-276.
17. Chadha MK, Fakih M, Muindi J, Tian L, Mashtare T, et al. (2011) Effect of 25- hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients. Prostate 71: 368-372.
18. Loeb M, Russell ML, Moss L, Fonseca K, Fox J, et al. (2010) Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 303: 943-950.
19. Langlois K, Greene-Finestone L, Little J, Hidiroglou N, Whiting S (2010) Vitamin D status of Canadians as measured in the 2007 to 2009 Canadian Health Measures Survey. Health Rep 21: 47-55.
20. Maguire JL, Birken CS, O'Connor DL, Macarthur C, Thorpe KE, et al. (2011) Prevalence and predictors of low vitamin D concentrations in urban Canadian toddlers. Paediatr Child Health 16: e11-15.
21. Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML (2009) Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics 124: e362-370.
22. Public Health Agency of Canada (2009) Flu Watch May 31, 2009 to June 6, 2009. Available: http://www.phac-aspc.gc.ca/fluwatch/08-09/w22-09/indexeng.php. Accessed: 4 Oct 2009.
23. Food and Drug Administration (2007) Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. Available: http://www.fda.gov/ downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ Guidances/Vaccines/ucm091985.pdf. Accessed: 25 Oct 2012.
24. Committee for Proprietary Medicinal Products (1997) Note for guidance on harmonisation of requirements for influenza vaccines. Available: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003945.pdf. Accessed: 25 Oct 2012.
25. Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, et al. (2011) Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 30: 1081-1085.
26. Principi N, Marchisio P, Terranova L, Zampiero A, Baggi E, et al. (2013) Impact of vitamin D administration on immunogenicity of trivalent inactivated influenza vaccine in previously unvaccinated children. Hum Vaccin Immunother 9.
27. Sundaram ME, Talbot HK, Zhu Y, Griffin MR, Spencer S, et al. (2013) Vitamin D is not associated with serologic response to influenza vaccine in adults over 50 years old. Vaccine 31: 2057-2061.
28. Hannoun C, Megas F, Piercy J (2004) Immunogenicity and protective efficacy of influenza vaccination. Virus Res 103: 133-138. (Pubitemid 38649072)
29. Maguire JL, Birken CS, Khovratovich M, Degroot J, Carsley S, et al. (2013) Modifiable determinants of serum 25-hydroxyvitamin D status in early childhood: opportunities for prevention. JAMA Pediatr 167: 230-235.